Notice of correction of paid-in capital increase allocated to third parties

Hello, shareholders, I wish you good health and good luck in your family.

Due to the request of the relevant agency to adjust the schedule of the payment date of the paid-in capital increase of the third party, which was decided by the board of directors on April 19, 2022

Through the board of directors meeting held on May 09, 2022, we decided to change the payment date as follows and re-announce it to shareholders in accordance with Article 418 (4) of the Commercial Act.

1. Type and number of new shares: registered common shares 522,032 shares

2. Issuance price of new shares: KRW 20,880 per share (issue a face value of KRW 500 surcharge)

3. Method of issuing new shares: Third-party allocation method (in accordance with Article 418 (2) of the Commercial Act and Article 9 (2) 11 of the articles of incorporation of the Company)

4. Purpose of financing: achievement of management purpose and prompt financing (procurement of facilities and operating funds)

5. Total issuance of new shares: KRW 10,900,028,160

6. Subject to issue of new shares

* The name of the subject of issuance, the amount of investment, and the schedule of paid-in capital increase may be changed according to the adjustment process of the relevant institution.

7. Estimated payment date: 2022.05.20

8. Other matters

A) Other detailed matters concerning the issuance of new shares shall be delegated to the CEO.

B) This paid-in capital increase schedule may be changed according to the adjustment process of the relevant agency.

C) Disposal of forfeited shares: Disclaimer shares that are not subscribed or acquired by the assignee are not issued.

As described above, we are notifying you of the paid-in capital increase assigned to a third party, and if you have any questions or objections, please contact us by 05/19/2022.

May 9th, 2022

HEM Pharma

   ​